May 8th 2025
Founder and CEO of Alume Biosciences, Quyen Nguyen, MD, PhD, discusses nerve regeneration, nerve visualization and the reason behind what she does at Alume Biosciences.
You deserve the spotlight. Your work educates, informs, and empowers decisions that save lives—and now it’s time for the industry to take notice.
Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support
May 7th 2025Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
Asembia 2025: Tracking Long-Term Outcomes Key to Advanced Therapy Value
May 6th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies and support future payment strategies.
Lilly Bolsters ALS Pipeline Through $415 Million Licensing Agreement with Alchemab Therapeutics
May 6th 2025Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly will assume responsibility for further development and commercialization of the novel platform.
Herspiegel Consulting Dives Into the Value Narrative
May 6th 2025Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients have easier access to healthcare information, and the exciting future of pharmaceutical manufacturing and patient care.
FDA Issues Refusal to File for ImmunityBio’s sBLA for Anktiva in BCG-Unresponsive NMIBC
May 6th 2025The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application for Anktiva in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.
Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare
May 5th 2025Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.